Detalles de la búsqueda
1.
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.
Ann Oncol;
35(3): 248-266, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38307807
2.
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.
Br J Cancer;
128(8): 1503-1513, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36759720
3.
Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.
Ann Oncol;
34(2): 152-162, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36564284
4.
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.
Ann Oncol;
34(12): 1152-1164, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37797734
5.
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
Ann Oncol;
34(8): 681-692, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37211045
6.
Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer.
Gynecol Oncol;
174: 80-88, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37167896
7.
Benign descriptors and ADNEX in two-step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohort.
Ultrasound Obstet Gynecol;
61(2): 231-242, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36178788
8.
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
Ann Oncol;
33(6): 593-601, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35219776
9.
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer.
Ann Oncol;
33(3): 276-287, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34861371
10.
Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe.
Gynecol Oncol;
167(1): 3-10, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36085090
11.
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
Ann Oncol;
32(6): 757-765, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33667670
12.
Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer.
Breast Cancer Res Treat;
185(1): 183-194, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32980945
13.
Safety and efficiency of performing transvaginal ultrasound-guided tru-cut biopsy for pelvic masses.
Gynecol Oncol;
161(3): 845-851, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33858675
14.
ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumors.
Ultrasound Obstet Gynecol;
58(1): 148-168, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33794043
15.
A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel.
Gynecol Oncol;
156(2): 293-300, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31826802
16.
Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
Gynecol Oncol;
157(1): 245-251, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31980219
17.
Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors.
Gynecol Oncol;
159(3): 811-819, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32994054
18.
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Gynecol Oncol;
159(2): 442-448, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32981695
19.
Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies.
Gynecol Oncol;
156(2): 308-314, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31822399
20.
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
Ann Oncol;
30(5): 672-705, 2019 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31046081